Alpine Associates Management’s Terns Pharmaceuticals TERN Stock Holding History

Alpine Associates Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-142,250	Closed	-$7.5M	–	93
2026 Q1	$7.5M	Buy	+142,250	New	+$5.84M	0.44%	51

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Alpine Associates Management's TERN Position: Q2 2026 in Review

Alpine Associates Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 142,250 shares — an estimated $7.5M sold.

Alpine Associates Management first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $7.5M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Alpine Associates Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Alpine Associates Management sold 142,250 Terns Pharmaceuticals shares in Q2 2026, an estimated $7.5M.
Alpine Associates Management first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Alpine Associates Management's Terns Pharmaceuticals position peaked at $7.5M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Alpine Associates Management's 13F filing for Q2 2026, filed 6 Aug 2026.